Current Illinois CancerCare Clinical Trials

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Study Number: A222004

Study Summary:
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.

Status: Coming Soon

Open at all clinics

No use of androgens, progesterone analogs, or other appetite stimulants within the past month.

Study Coordinator(s)
  • Navigator Courtney, 309-243-3660 cbrown@illinoiscancercare.com
  • Hannah S, 309-243-3603, hshearburn@illinoiscancercare.com
  • Kelsey, 309-243-3618 kfay@illinoiscancercare.com

Study Link

« Search Again